CRYOPORT, INC. Debt Securities, Available-for-sale, Unrealized Loss Position
CRYOPORT, INC. (CYRX) had Debt Securities, Available-for-sale, Unrealized Loss Position of $1.86 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $1.86M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $2.35M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $3.47M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $3.76M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $1.86M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.35M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $3.47M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.76M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $4.64M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $6.35M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $7.59M 10-K · filed 2025-03-07 |
| 2024-06-30 | $637.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $633.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $22.00K 10-K · filed 2024-03-13 |
| 2023-09-30 | $502.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $282.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $224.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $24.69M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |